- Home
- FLYE vs ADAG Comparison
FLYE vs ADAG Comparison
Compare FLYE & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- ADAG
- Stock Information
- Founded
- FLYE 2018
- ADAG 2011
- Country
- FLYE United States
- ADAG China
- Employees
- FLYE N/A
- ADAG N/A
- Industry
- FLYE Aerospace
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- ADAG Health Care
- Exchange
- FLYE Nasdaq
- ADAG Nasdaq
- Market Cap
- FLYE 91.6M
- ADAG 90.8M
- IPO Year
- FLYE 2024
- ADAG 2021
- Fundamental
- Price
- FLYE $6.76
- ADAG $2.31
- Analyst Decision
- FLYE
- ADAG Strong Buy
- Analyst Count
- FLYE 0
- ADAG 2
- Target Price
- FLYE N/A
- ADAG $7.50
- AVG Volume (30 Days)
- FLYE 1.9M
- ADAG 100.8K
- Earning Date
- FLYE 08-19-2025
- ADAG 08-19-2025
- Dividend Yield
- FLYE N/A
- ADAG N/A
- EPS Growth
- FLYE N/A
- ADAG N/A
- EPS
- FLYE N/A
- ADAG N/A
- Revenue
- FLYE $25,427,163.00
- ADAG $103,204.00
- Revenue This Year
- FLYE N/A
- ADAG $9,289.17
- Revenue Next Year
- FLYE N/A
- ADAG $36.84
- P/E Ratio
- FLYE N/A
- ADAG N/A
- Revenue Growth
- FLYE N/A
- ADAG N/A
- 52 Week Low
- FLYE $1.65
- ADAG $1.33
- 52 Week High
- FLYE $8.30
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- ADAG 58.27
- Support Level
- FLYE N/A
- ADAG $1.86
- Resistance Level
- FLYE N/A
- ADAG $2.60
- Average True Range (ATR)
- FLYE 0.00
- ADAG 0.16
- MACD
- FLYE 0.00
- ADAG 0.03
- Stochastic Oscillator
- FLYE 0.00
- ADAG 42.11
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.